Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Y-mAbs Therapeutics A/S
A/S
Active
Advertising protection
CVR 37053678
Agern Alle 13, 2970
Hørsholm
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2015 · 10 years old
16 employees
Monitor
Share
Denmark
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Y-mAbs Therapeutics A/S
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Gross profit
DKK millions
102M
77M
51M
26M
0M
2021: 68M
68M
2021
2022: 82M (+21% vs 2021)
82M
+21%
2022
2023: 71M (-13% vs 2022)
71M
-13%
2023
2024: 74M (+4% vs 2023)
74M
+4%
2024
2025: 29M (-61% vs 2024)
29M
-61%
2025
EBITDA
DKK millions
0M
-14M
-29M
-43M
-57M
2021: -38M
-38M
2021
2022: -46M (-21% vs 2021)
-46M
-21%
2022
2023: -20M (+57% vs 2022)
-20M
+57%
2023
2024: -1M (+95% vs 2023)
-1M
+95%
2024
2025: -45M (-4400% vs 2024)
-45M
-4400%
2025
Income statement
DKK thousands
Item
2025
2024
2023
2022
2021
Gross profit
29.300
74.263
70.656
82.332
67.550
Staff expenses
-74.607
-75.459
-90.965
-128.511
-105.682
EBITDA
-45.306
-1.196
-20.082
-46.338
-38.133
Depreciation & amort.
-2.813
-191
-806
-30.492
-2.082
EBIT
-48.119
-1.388
-20.888
-76.830
-40.215
Net financials
-10.827
-11.113
-6.860
-8.856
-1.873
Profit before tax
-58.946
-12.500
-27.749
-85.686
-42.088
Tax
-20.485
-0
-0
-0
-0
Net profit
-38.462
-12.500
-27.749
-85.686
-42.088
Balance sheet
DKK thousands
Item
2025
2024
2023
2022
2021
Total assets
15.043
26.470
56.658
22.906
61.472
Equity
-163.652
-125.190
-112.690
-84.941
-39.255
Long-term debt
6.065
5.829
8.264
11.600
8.379
Short-term debt
172.630
145.832
161.084
96.246
92.348
Total debt
178.695
151.661
169.348
107.847
100.727
Financial ratios
5-year trend
EBITDA margin (of gross profit)
-154,6 %
This company
2021
2025
Equity ratio
<−999 %
This company
38,2 %
Market median
This company
Market median
>999% below market
2021
2025
Return on equity
—
This company
18,4 %
Market median
This company
Market median
2021
2025
Net profit margin (of gross profit)
-131,3 %
This company
2021
2025
Asset turnover (of gross profit)
1,95×
This company
2021
2025
Debt / equity
—
This company
0,62×
Market median
This company
Market median
2021
2025
Annual reports & filings
Annual report 2025
Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
View
PDF
More on Y-mAbs Therapeutics A/S
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
